Curaleaf shares fall post FDA’s warning issued over false CBD claims
Category: #health  By Pankaj Singh  Date: 2019-07-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Curaleaf shares fall post FDA’s warning issued over false CBD claims
  • The FDA warning had come after Curaleaf made unsubstantiated claims that their CBD (cannabidiol) based products can treat serious diseases.
     
  • Curaleaf has been asked to respond within 15 days with its plans to mitigate the violations.

Curaleaf Holdings Inc., (Curaleaf), a medical and wellness cannabis operator in the U.S., has reportedly received a warning from the U.S. Food and Drug Administration (FDA) for marketing CBD products using unsubstantiated claims that they treat serious illnesses.

Curaleaf shares tumbled by as much as 8% after the FDA issued the warning. CBD is a non-intoxicating component of cannabis plant which is said to have health benefits, however, there hasn’t been a lot of research to support these claims yet.

According to reports, The FDA began regulation of CBD in 2018, after hemp was legalized under the Farm Bill, and made it clear that it classifies CBD as a drug since it had been the main ingredient of Epidiolex, America’s only cannabis-based drug that is FDA-approved, to treat serious childhood epilepsy.

The FDA issued the warning letter to Curaleaf for selling prohibited and unauthorized products containing CBD with claims that they treat serious ailments such as Alzheimer’s disease, cancer, pet and pain anxiety and opioid withdrawal among others.

FDA Commissioner Ned Sharpless stated that as the FDA continues to examine pathways for legal marketing of products that contain cannabis and components derived from cannabis, its main motive would still be the promotion and protection of public health. Sharpless further stated that sale of unauthorized products using unsubstantiated claims could put a patient’s life at risk by causing them to avoid crucial medical care.

For the record, FDA has instructed companies to not use CBD in food and beverages, however, it tolerates its presence in topical products until firms don’t make any serious health claims.

Curaleaf has been asked to respond within 15 days with its plans to mitigate the violations. Failure to correct the violations could result in legal action, including confiscation of product and injunction.

Source Credits: https://www.marketwatch.com/story/curaleaf-shares-tumble-8-after-fda-warning-letter-over-cbd-health-claims-2019-07-23

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
By Pankaj Singh

Genentech, Inc., a subsidiary of the Roche Group, has reportedly announced the completion of a sBLA (supplemental Biologics License Application) submission to the U.S. FDA (Food and Drug Administration) for Tecentriq ® (atezolizumab) in combinati...

FDA issues a cybersecurity warning for GE medical equipment
FDA issues a cybersecurity warning for GE medical equipment
By Pankaj Singh

The U.S. Food and Drug Administration, an agency within the U.S. Department of Health and Human Services, recently issued a safety communication informing patients, health care providers and facilities regarding the cybersecurity vulnerabilities...

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...